IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and
operational results for the three and nine month periods ended September 30,
2009.


Highlights:

- Substantial Contract Research revenue increase over third quarter 2008.

- Positive clinical results for bioFILM PA(TM) will assist market introduction
of the kit. The company expects first product sales in the fourth quarter 2009.


- Agricultural biocide product Agress(TM) again demonstrates its effectiveness
in a growing number of applications.


"The strong revenue results in Contract Research have enabled the Company to
continue and increase its spending on marketing and development efforts as it
brings its two lead products, bioFILM PA in Human Health and Agress in
Agriculture, to market. The Company has done this while maintaining adequate
cash reserves" says Dr. James Timourian, Chief Financial Officer. "In July the
Company presented positive clinical outcome data on the use of the bioFILM PA
test kit in clinics in Edmonton and Innovotech is now working to make the test
kit easily available for Cystic Fibrosis patients across Canada. The results of
field tests with Agress exceeded expectations as more applications are being
found for this crop treatment product. Agress is environmentally friendly, cost
effective, and is compatible with current products."




Financial Summary

----------------------------------------------------------------------------
               Three-month     Three-month      Nine-month       Nine-month
           period ended 30 period ended 30 period ended 30  period ended 30
($)         September 2009  September 2008  September 2009   September 2009
----------------------------------------------------------------------------
Revenues           399,728        247,890          989,425          966,165
----------------------------------------------------------------------------
G&A                262,363        232,514          759,496          678,330
----------------------------------------------------------------------------
R&D                256,689        235,731          657,696          503,512
----------------------------------------------------------------------------
Net Income
 (loss)        (358,746)(i)      (339,258)      (1,013,566)        (652,869)
----------------------------------------------------------------------------
Cash-on-hand                                      1,485,080        2,014,900
----------------------------------------------------------------------------
----------------------------------------------------------------------------

(i) Includes a non-cash entry for options ($95,823) to key employees related
    to the corporate relocation to Edmonton.



About Innovotech Inc:

Innovotech is a product development company focusing on the development of
solutions to medical, agricultural and industrial problems caused by microbial
biofilms. Biofilms are protected communities of microorganisms which are very
common and very difficult to treat due to their inherent resistance. The company
currently has two products in advanced stages of development: bioFILM PA is a
diagnostic kit which assists physicians in the selection of the most effective
antibiotic treatment of patients with chronic lung infections. Agress(tm) is a
novel seed treatment product that protects seeds during the critical germination
and emergence stage from bacterial and fungal infection.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024